IRLAB Therapeutics AB (IRLAB-A) Fair Value & Analysis
Healthcare · SE · Market cap 121M SEK
Fair value as of: Jul 13, 2026
From 3 valuation models · updated 8 days ago
Share price +1.1% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 1.20 – kr 3.63 · fair‑value band kr 0.2465 – kr 0.6120 · the kr 1.26 price screens above the kr 0.4420 fair value. As of Jul 13, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
IRLAB Therapeutics AB (IRLAB-A) currently trades at kr 1.26, while our model-based Fair Value estimate is kr 0.4420, implying the stock looks roughly 64.9% overvalued today. We read business quality at 24/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, IRLAB Therapeutics AB generated revenue of 92.5M SEK at a net margin of -72.4%. The balance sheet holds a net cash position of 51.9M SEK. Fundamentals as of Jul 13, 2026
Our scenario range runs from kr 0.2465 (bear case) to kr 0.6120 (bull case); at kr 1.26, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at -65%, IRLAB-A screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 13, 2026. TTM = trailing twelve months.
About the company
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pirepemat (IRL752), which is in a Phase IIB clinical trial to reduce the risk of falling and falls in Parkinson's disease, and in a Phase IIA clinical trial for dementia in Parkinson's disease; and IRL757, which is in a Phase I clinical trial for the treatment of apathy in Parkinson's and other neurological disorders. It is also developing products in the preclinical stage, such as IRL942, an oral tablet for the treatment of cognitive deficits in Parkinson's and other neurological disorders; and IRL1117, an oral treatment for the hallmark symptoms of Parkinson's. In addition, the company …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
IRLAB Therapeutics AB reported revenue of kr 57.5M in FY2025 versus kr 208M in FY2021, a compound −27.5%/yr. Reported net income was −kr 110M in FY2025.
Is IRLAB-A fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 4,803 MXN | -38% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.04 | R$46.95 | -10% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$102.95 | A$126.79 | +23% |
| Celltrion, Inc 068270 | 183,600 KRW | 76,325 KRW | -58% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| WuXi Biologics (Cayman) Inc 2269 | HK$32.74 | HK$24.99 | -24% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is IRLAB Therapeutics AB (IRLAB-A) undervalued?
What is the fair value of IRLAB-A?
What is the quality score of IRLAB-A?
What is the revenue of IRLAB Therapeutics AB (IRLAB-A)?
What is the net profit margin of IRLAB-A?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full IRLAB Therapeutics AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.